Bipolar disorder: involvement of signaling cascades and AMPA receptor trafficking at synapses.
- Authors
- Du, Jing; Quiroz, Jorge; Yuan, Peixiong; Zarate, Carlos; Manji, Husseini K
- Year
- 2004
- Journal
- Neuron glia biology
- PMID
- 18634600
- DOI
- 10.1017/S1740925X05000098
- PMCID
- PMC2763507
There is increasing evidence that severe mood disorders are associated with impairment of structural plasticity and cellular resilience. Cumulative data demonstrate that mood stabilizers regulate intracellular signaling cascades, including protein kinase C (PKC), PKA, mitogen-activated protein (MAP) kinase, glycogen synthase kinase 3-beta (GSK3-beta) and intracellular calcium, which are signaling pathways that regulate synaptic plasticity. In this context, it is noteworthy that a growing body of data indicates that the glutamatergic system, has a major role in neuronal plasticity and cellular resilience, might be involved in the pathophysiology and treatment of mood disorders. AMPA glutamate-receptor trafficking is important in synaptic plasticity and might play crucial roles in maintaining critical neuronal circuits associated with mood. Two clinically effective, structurally dissimilar, antimanic agents, lithium and valproate (VPA), down-regulate synaptic expression of AMPA receptor subunit GluR1 in hippocampus in chronically treated rats. This reduction in synaptic GluR1 by lithium and VPA is due to attenuated phosphorylation of GluR1 at a specific PKA site (residue 845 of GluR1), which is crucial for AMPA receptor insertion. By contrast,imipramine, which can provoke mania, increases synaptic expression of GluR1 in the hippocampus in vivo. Furthermore, there is ample evidence from preclinical and clinical research that the glutamatergic system is involved in the pathophysiology of mood disorders and that many of the somatic treatments used for mood disorders including antidepressants, mood stabilizers, atypical antipsychotic drugs and electroconvulsive therapy have both direct and indirect effects on the glutamatergic system. Given these findings, further research with medications that specifically affect the glutamatergic system is warranted. Recent studies in our lab have shown that riluzole, a FDA approved medicine that regulates the glutamatergic system, shows antidepressant efficacy in unipolar and bipolar depression. These studies indicate that regulation of glutamate-mediated synaptic plasticity might play a role in the treatment of mood disorders, and raise new avenues for novel therapies for this devastating illness.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Analyzing the potential of neuronal pentraxin 2 as a biomarker in neurological disorders: A literature review. | Ansari U et al. | β | 2024 | β |
| Use of gene regulatory network analysis to repurpose drugs to treat bipolar disorder. | Truong TTT et al. | β | 2024 | β |
| Lithium causes differential effects on postsynaptic stability in normal and denervated neuromuscular synapses. | Zelada D et al. | β | 2021 | β |
| Investigation of the impact of an <i>ADCY2</i> polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran. | Aghabozorg Afjeh SS et al. | β | 2020 | β |
| Study of 45 candidate genes suggests CACNG2 may be associated with lithium response in bipolar disorder. | Miranda A et al. | β | 2019 | β |
| The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants? | Frizzo ME | β | 2019 | β |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | β | 2019 | β |
| High-fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. | Alten B et al. | β | 2018 | β |
| Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia. | Liu YN et al. | β | 2017 | β |
| Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling. | Gideons ES et al. | β | 2017 | β |
| Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. | Tomasetti C et al. | β | 2017 | β |
| 3'-Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. | Li B et al. | β | 2016 | β |
| Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. | Mertens J et al. | β | 2015 | β |
| Effect of desipramine on gene expression in the mouse frontal cortex - microarray study. | Solich J et al. | β | 2015 | β |
| AprioriGWAS, a new pattern mining strategy for detecting genetic variants associated with disease through interaction effects. | Zhang Q et al. | β | 2014 | β |
| Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain. | Mavrikaki M et al. | β | 2014 | β |
| Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex. | Sui L et al. | β | 2013 | β |
| Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level. | GΔ ska M et al. | β | 2012 | β |
| Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. | de Bartolomeis A et al. | β | 2012 | β |
| Systems biology, bioinformatics, and biomarkers in neuropsychiatry. | Alawieh A et al. | β | 2012 | β |
| Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. | Szabo ST et al. | β | 2009 | β |
| Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine. | Large CH et al. | β | 2009 | β |
| Neurobiological trait abnormalities in bipolar disorder. | Langan C et al. | β | 2009 | β |
| Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. | Du J et al. | β | 2006 | β |